NCT07050823 Mitigating Chronic Respiratory Disease Through the Lens of Multi-Morbidity
| NCT ID | NCT07050823 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University College, London |
| Condition | Chronic Obstructive Pulmonary Disease (COPD) |
| Study Type | OBSERVATIONAL |
| Enrollment | 859 participants |
| Start Date | 2025-07-01 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 859 participants in total. It began in 2025-07-01 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The investigators aim to make it easier to find people with undiagnosed long-term lung health problems (such as asthma, and chronic obstructive pulmonary disease, COPD, collectively called 'Chronic Respiratory Diseases', CRDs) living in Brasil. Because people with undiagnosed CRDs often have other medical problems too, such as heart problems, high blood pressure and diabetes (collectively called 'Long Term Conditions', LTC), the investigators will look for undiagnosed CRD in people with LTC when they are attending appointments at local health centres in the cities of Sao Carlos and Sao Paulo. To look for undiagnosed CRDs the investigators will use two questionnaire-based methods called 'COLA' and 'SBQ'. These are quick and simple to do. All participants will also have tests of their lung function completed including spirometry and Fractional Exhaled Nitric Oxide so that the investigators can make a definite diagnosis of CRDs. When the study is complete, the investigators will examine how well the COLA and SBQ questionnaires perform in identifying people with a definite diagnosis of CRD. In total, the investigators aim to recruit 859 people.
Eligibility Criteria
Inclusion Criteria: Attending primary health care services in Brasil. Diagnosed with one or more existing, non-respiratory long-term conditions such as cardiovascular disease, diabetes or hypertension. Exclusion Criteria: Clinically unstable in the past month (defined as worsening symptoms requiring emergency care or hospitalization). Current pregnancy. Active pulmonary tuberculosis or undergoing treatment for pulmonary tuberculosis. Current acute respiratory infection. Cognitive impairment that prevents understanding of the case-finding questionnaire, defined as MMSE score ≤20. Contraindications to spirometry. Declines to participate in the study.
Contact & Investigator
John R Hurst, PhD FRCP
PRINCIPAL INVESTIGATOR
University College London Hospitals
Frequently Asked Questions
Who can join the NCT07050823 clinical trial?
This trial is open to participants of all sexes, aged 30 Years or older, studying Chronic Obstructive Pulmonary Disease (COPD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07050823 currently recruiting?
Yes, NCT07050823 is actively recruiting participants. Contact the research team at vivianecastello@ufscar.br for enrollment information.
Where is the NCT07050823 trial being conducted?
This trial is being conducted at São Carlos, Brazil, São Paulo, Brazil.
Who is sponsoring the NCT07050823 clinical trial?
NCT07050823 is sponsored by University College, London. The principal investigator is John R Hurst, PhD FRCP at University College London Hospitals. The trial plans to enroll 859 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.